ArticleNature2023
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 96 citations in OpenAlex.
- CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.Nature medicine · 2026Trial
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia.Oncoimmunology · 2026Article
- Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease.Cell stem cell · 2026Article
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Editing around the target: epitope engineering to protect stem cell grafts.Blood advances · 2026Review
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Article
- CRISPR application in hematological disorders: from bench to bedside.Blood advances · 2026Review
- CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.Genome medicine · 2026Article
- CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia model.bioRxiv : the preprint server for biology · 2026Article
- Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters.Nature biotechnology · 2026Article
- First-in-human study of FLT3 CAR-T cell therapy for relapsed acute myeloid leukemia.NPJ precision oncology · 2026Article
- CRISPR Genome Editing and the Future of Leukaemia Immunotherapy.Health science reports · 2026Article
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- Article
- Combinatorial base editing couples disease correction with lineage amplification in hematopoietic stem and progenitor cells.bioRxiv : the preprint server for biology · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- The Caspase-1-EGR4 axis regulates macrophage repolarization in acute myeloid leukemia cells.Scientific reports · 2026Article
- Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond.Cell reports. Medicine · 2026Review
- Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.Annals of hematology · 2026Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 4 countries.
Gabriele CasiratiDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0003-1925-1195
Andrea CosentinoDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Adele MucciDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Mohammed Salah MahmoudDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-9190-6590
Iratxe Ugarte ZabalaDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Jing ZengDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Scott B FicarroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Denise KlattDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Christian BrendelDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Alessandro RambaldiDepartment of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.ORCID 0000-0002-3739-7502
Jerome RitzDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0001-5526-4669
Jarrod A MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2086-1134
Danilo PellinDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-2647-0508
Daniel E BauerDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Scott A ArmstrongDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-9099-4728
Pietro GenoveseDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. Pietro_Genovese@dfci.harvard.edu.ORCID 0000-0001-9507-9003
Boston Children's Hospital · USBrigham and Women's Hospital · USOspedale Papa Giovanni XXIII · IT
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MIlluminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6MTargeting to Epigenetic Modications in ALLR01CA176745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A, QI, JUN · 2012 to 2022
$4.2MNovel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5MDevelopment, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 ImmunodeficiencyR01AI155796 · NIAID · DANA-FARBER CANCER INST · PI GENOVESE, PIETRO · 2021 to 2025
$2.2MDefining epigenetic mechanisms in NPM1c mutant leukemiaR01CA259273 · NCI · DANA-FARBER CANCER INST · PI ARMSTRONG, SCOTT A · 2021 to 2025
$2.0MTools for DUB Drug DiscoveryR21CA247671 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2020 to 2021
$648kNCI NIH HHS P01 CA066996NCI NIH HHS R01 CA176745NCI NIH HHS R01 CA233800NCI NIH HHS R01 CA259273NCI NIH HHS R21 CA247671NIAID NIH HHS R01 AI155796NIDDK NIH HHS U24 DK116204
Abstract
Despite the considerable efficacy observed when targeting a dispensable lineage antigen, such as CD19 in B cell acute lymphoblastic leukaemia
Indexed as
EpitopesGene EditingImmunotherapyLeukemia, Myeloid, AcuteAnimalsAntibodies, MonoclonalAntigens, CD34Bone Marrow TransplantationEpitope Mappingfms-Like Tyrosine Kinase 3HematopoiesisHematopoietic Stem CellsHeterograftsHumansInterleukin-3 Receptor alpha SubunitProto-Oncogene Proteins c-kitAntibodies, MonoclonalAntigens, CD34EpitopesFLT3 protein, humanfms-Like Tyrosine Kinase 3IL3RA protein, humanInterleukin-3 Receptor alpha SubunitKIT protein, humanProto-Oncogene Proteins c-kitReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.